<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Prev Med</journal-id><journal-id journal-id-type="iso-abbrev">Int J Prev Med</journal-id><journal-id journal-id-type="publisher-id">IJPVM</journal-id><journal-title-group><journal-title>International Journal of Preventive Medicine</journal-title></journal-title-group><issn pub-type="ppub">2008-7802</issn><issn pub-type="epub">2008-8213</issn><publisher><publisher-name>Medknow Publications &amp; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23776743</article-id><article-id pub-id-type="pmc">3678237</article-id><article-id pub-id-type="publisher-id">IJPVM-4-306</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Neuroprotective Effects of Erythropoietin in Acute Ischemic Stroke</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Asadi</surname><given-names>Bahador</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Askari</surname><given-names>Gholam Reza</given-names></name><xref ref-type="aff" rid="aff2">1</xref></contrib><contrib contrib-type="author"><name><surname>Khorvash</surname><given-names>Fariborz</given-names></name><xref ref-type="aff" rid="aff3">2</xref><xref ref-type="corresp" rid="cor1"></xref></contrib><contrib contrib-type="author"><name><surname>Bagherpur</surname><given-names>Ali</given-names></name><xref ref-type="aff" rid="aff3">2</xref></contrib><contrib contrib-type="author"><name><surname>Mehrabi</surname><given-names>Farzad</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Karimi</surname><given-names>Mohammad</given-names></name><xref ref-type="aff" rid="aff3">2</xref></contrib><contrib contrib-type="author"><name><surname>Ghasemi</surname><given-names>Majid</given-names></name><xref ref-type="aff" rid="aff4">3</xref></contrib><contrib contrib-type="author"><name><surname>Najjaran</surname><given-names>Abolfazl</given-names></name><xref ref-type="aff" rid="aff3">2</xref></contrib></contrib-group><aff id="aff1">Department of Neurology, Medical University of AJA, Tehran, Iran</aff><aff id="aff2"><label>1</label>Department of Community Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Science, Isfahan, Iran</aff><aff id="aff3"><label>2</label>Department of Neurology, Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran</aff><aff id="aff4"><label>3</label>Department of Neurology, Medical University of Shahid Beheshti, Tehran, Iran</aff><author-notes><corresp id="cor1"><bold>Correspondence to:</bold> Dr. Fariborz Khorvash, Department of Neurology, Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. E-mail: <email xlink:href="fkhorvash@med.mui.ac.ir">fkhorvash@med.mui.ac.ir</email></corresp></author-notes><pub-date pub-type="ppub"><month>5</month><year>2013</year></pub-date><volume>4</volume><issue>Suppl 2</issue><issue-title>8th Iranian Neurology Congress</issue-title><fpage>S306</fpage><lpage>S312</lpage><history><date date-type="received"><day>23</day><month>2</month><year>2013</year></date><date date-type="accepted"><day>23</day><month>2</month><year>2013</year></date></history><permissions><copyright-statement>Copyright: © International Journal of Preventive Medicine</copyright-statement><copyright-year>2013</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec id="st1"><title><offsets xml_i="4217" xml_f="4228" txt_i="11" txt_f="22">Background:</offsets></title><p><offsets xml_i="4239" xml_f="4523" txt_i="23" txt_f="307">Ischemic brain strokes consisttwo-thirdsof strokesand their complications bear a lot of disability for patient and society. In this study, we seek for effect of Erythropoietin on ischemic brain stroke's outcomes according to National Institutes of Health Stroke Scale (NIHSS) changes.</offsets></p></sec><sec id="st2"><title><offsets xml_i="4554" xml_f="4562" txt_i="309" txt_f="317">Methods:</offsets></title><p><offsets xml_i="4573" xml_f="4876" txt_i="318" txt_f="621">This study is a RCT (randomized clinical trial). All patients with focal neurologic deficit with primary suspicion of brain stroke undergone neuroimaging evaluations. After confirmation of new ischemic brain stroke, the patients with inclusion criteria’srandomized into two groups of cases and controls.</offsets></p><p><offsets xml_i="4883" xml_f="5373" txt_i="622" txt_f="1112">NIHSS was defined for each patient and all patients received a routine treatment protocol. Erythropoietin 16,000 IU as a bolus intravenous dose was given to case patients as soon as neuroimaging study confirmed new ischemic stroke and continued as 8000 IU each 12 h up to total dose of 56,000 IU during 3 days. Patients re-evaluated at days 14 and 28 and NIHSS was assessed by another neurologist blinded to patient's group. Finally, NIHSS changes of both groups compared with each other's.</offsets></p></sec><sec id="st3"><title><offsets xml_i="5404" xml_f="5412" txt_i="1114" txt_f="1122">Results:</offsets></title><p><offsets xml_i="5423" xml_f="5523" txt_i="1123" txt_f="1223">Evaluations revealed that in days14 and 28 during follow-up, Erythropoietin was effective in NIHSS (</offsets><italic><offsets xml_i="5531" xml_f="5532" txt_i="1223" txt_f="1224">P</offsets></italic><offsets xml_i="5541" xml_f="5613" txt_i="1224" txt_f="1296">= 0.0001). This effect was of value in level of consciousness Commands (</offsets><italic><offsets xml_i="5621" xml_f="5622" txt_i="1296" txt_f="1297">P</offsets></italic><offsets xml_i="5631" xml_f="5655" txt_i="1297" txt_f="1321">= 0.024), facial palsy (</offsets><italic><offsets xml_i="5663" xml_f="5664" txt_i="1321" txt_f="1322">P</offsets></italic><offsets xml_i="5673" xml_f="5694" txt_i="1322" txt_f="1343">= 0.003), motor arm (</offsets><italic><offsets xml_i="5702" xml_f="5703" txt_i="1343" txt_f="1344">P</offsets></italic><offsets xml_i="5712" xml_f="5734" txt_i="1344" txt_f="1366">= 0.0001), motor leg (</offsets><italic><offsets xml_i="5742" xml_f="5743" txt_i="1366" txt_f="1367">P</offsets></italic><offsets xml_i="5752" xml_f="5772" txt_i="1367" txt_f="1387">= 0.0001), sensory (</offsets><italic><offsets xml_i="5780" xml_f="5781" txt_i="1387" txt_f="1388">P</offsets></italic><offsets xml_i="5790" xml_f="5819" txt_i="1388" txt_f="1417">= 0.009), and best language (</offsets><italic><offsets xml_i="5827" xml_f="5828" txt_i="1417" txt_f="1418">P</offsets></italic><offsets xml_i="5837" xml_f="5846" txt_i="1418" txt_f="1427">= 0.023).</offsets></p></sec><sec id="st4"><title><offsets xml_i="5877" xml_f="5889" txt_i="1429" txt_f="1441">Conclusions:</offsets></title><p><offsets xml_i="5900" xml_f="6063" txt_i="1442" txt_f="1605">Administration of high-dose erythropoietin in first 24 h can be effective on reduction of ischemic stroke complication. A larger scale clinical trial is warranted.</offsets></p></sec></abstract><kwd-group><kwd>Erythropoietin</kwd><kwd>national institutes of health stroke scale</kwd><kwd>neuroprotection</kwd><kwd>stroke</kwd></kwd-group></article-meta></front><body><sec id="sec1-1"><title><offsets xml_i="6281" xml_f="6293" txt_i="1614" txt_f="1626">INTRODUCTION</offsets></title><p><offsets xml_i="6304" xml_f="6414" txt_i="1627" txt_f="1737">Stroke is the third most common cause of death and the most leading cause of disability in the United States.[</offsets><xref ref-type="bibr" rid="ref1"><offsets xml_i="6447" xml_f="6448" txt_i="1737" txt_f="1738">1</offsets></xref><offsets xml_i="6455" xml_f="6456" txt_i="1738" txt_f="1739">–</offsets><xref ref-type="bibr" rid="ref5"><offsets xml_i="6489" xml_f="6490" txt_i="1739" txt_f="1740">5</offsets></xref><offsets xml_i="6497" xml_f="6569" txt_i="1740" txt_f="1812">] Annually, 750,000 new cases are recorded with 150,000-200,000 deaths.[</offsets><xref ref-type="bibr" rid="ref2"><offsets xml_i="6602" xml_f="6603" txt_i="1812" txt_f="1813">2</offsets></xref><offsets xml_i="6610" xml_f="6611" txt_i="1813" txt_f="1814">–</offsets><xref ref-type="bibr" rid="ref4"><offsets xml_i="6644" xml_f="6645" txt_i="1814" txt_f="1815">4</offsets></xref><offsets xml_i="6652" xml_f="6753" txt_i="1815" txt_f="1916">] 80% of all strokes are ischemic and the remindersare hemorrhagic including subarcnoide hemorrhage.[</offsets><xref ref-type="bibr" rid="ref4"><offsets xml_i="6786" xml_f="6787" txt_i="1916" txt_f="1917">4</offsets></xref><offsets xml_i="6794" xml_f="6795" txt_i="1917" txt_f="1918">]</offsets></p><p><offsets xml_i="6802" xml_f="7085" txt_i="1919" txt_f="2202">Stroke is a syndrome with acute neurologic deficit, which lasts at least 24 h and is directly due to impairment of cerebral blood-flow and central nervous system involvement. If symptoms revealed before 24 h (usually during 30 min), the term TIA (Transient Ischemic Attack) applies.[</offsets><xref ref-type="bibr" rid="ref6"><offsets xml_i="7118" xml_f="7119" txt_i="2202" txt_f="2203">6</offsets></xref><xref ref-type="bibr" rid="ref7"><offsets xml_i="7159" xml_f="7160" txt_i="2203" txt_f="2204">7</offsets></xref><offsets xml_i="7167" xml_f="7168" txt_i="2204" txt_f="2205">]</offsets></p><p><offsets xml_i="7175" xml_f="7615" txt_i="2206" txt_f="2646">Stroke can lead to hemiplegia, numbness, paresthesia, confusion, mental deficit, speech and language disorder, diplopia, visual field defect, and coma. Multiple risk factors are recognized for stroke. Hypertension, Chronic Heart Failure, Arterial Fibrillation, Diabetes Mellitus, long-term smoking, hyperlipidemia, and increased low density lipoprotein are the most common. Hyper-coagulation states and oral contraceptives are less common.[</offsets><xref ref-type="bibr" rid="ref8"><offsets xml_i="7648" xml_f="7649" txt_i="2646" txt_f="2647">8</offsets></xref><offsets xml_i="7656" xml_f="7657" txt_i="2647" txt_f="2648">–</offsets><xref ref-type="bibr" rid="ref13"><offsets xml_i="7691" xml_f="7693" txt_i="2648" txt_f="2650">13</offsets></xref><offsets xml_i="7700" xml_f="7701" txt_i="2650" txt_f="2651">]</offsets></p><p><offsets xml_i="7708" xml_f="7879" txt_i="2652" txt_f="2823">Stroke incidence is increased with age. About two thirds of all strokes happen after 65 years old. Men are slightly more affected than women and blacks are more involved.[</offsets><xref ref-type="bibr" rid="ref14"><offsets xml_i="7913" xml_f="7915" txt_i="2823" txt_f="2825">14</offsets></xref><offsets xml_i="7922" xml_f="7923" txt_i="2825" txt_f="2826">]</offsets></p><p><offsets xml_i="7930" xml_f="8104" txt_i="2827" txt_f="3001">Erythropoietin is made in human body and has erythropoietic effects. In addition, new studies suggest increased and enhanced angiogenesis and neurogenesis by erythropoietin.[</offsets><xref ref-type="bibr" rid="ref15"><offsets xml_i="8138" xml_f="8140" txt_i="3001" txt_f="3003">15</offsets></xref><offsets xml_i="8147" xml_f="8502" txt_i="3003" txt_f="3358">] erythropoietin is a glycoprotein, which is produced in kidneys and stimulates red cells syntheses in bone marrow. PD poetin is a recombinant erythropoietin, which is produced with recombinant DNA technology and has 165 aminoacids and molecular weight of 34000 Dalton. This drug mainly used in treatment of anemia in patients with chronic renal failure.[</offsets><xref ref-type="bibr" rid="ref16"><offsets xml_i="8536" xml_f="8538" txt_i="3358" txt_f="3360">16</offsets></xref><offsets xml_i="8545" xml_f="8546" txt_i="3360" txt_f="3361">]</offsets></p><p><offsets xml_i="8553" xml_f="8752" txt_i="3362" txt_f="3561">In this study, we wanted to know, if erythropoietin has any effect on acute ischemic stroke outcome and which disability of stroke shows more improvement in response to erythropoietin administration.</offsets></p></sec><sec sec-type="methods" id="sec1-2"><title><offsets xml_i="8805" xml_f="8812" txt_i="3563" txt_f="3570">METHODS</offsets></title><p><offsets xml_i="8823" xml_f="9017" txt_i="3571" txt_f="3765">All patients with focal neurologic deficit during first 24 h after attack, which were recognized as ischemic stroke were evaluated and those who reach inclusion criteria were entered this study.</offsets></p><p><offsets xml_i="9024" xml_f="9133" txt_i="3766" txt_f="3875">Including criteria planned as the first ischemic stroke, which confirmed by neuroimaging during initial 24 h.</offsets></p><p><offsets xml_i="9140" xml_f="9485" txt_i="3876" txt_f="4221">Exclusion criteria planned as: Existence of other intracranial pathology, Previous stroke, age over 80 years old, unstable systemic condition such as uncontrolled hypertension and Diabetes mellitus, polycythemia, and other myeloproliferative diseases, serum cratinine (Cr), history of deep vein thrombosis, and recent erythropoietin consumption.</offsets></p><p><offsets xml_i="9492" xml_f="10213" txt_i="4222" txt_f="4943">NIHSS was defined for each patient and all patients received a routine treatment protocol. Only patients with arterial fibrillation, coronary heart failure and vertebrobasilar stroke received Low molecular weight heparin. Patients randomized into two groups of cases and controls. Erythropoietin16,000 IU as a bolus intravenous dose was given to case patients as soon as neuroimaging study confirmed new ischemic stroke and continued as 8,000 IU each 12 h up to total dose of 56,000 IU during 3 days. Blood pressure assessed each 15 min at the first 2 h of each injection and serum level of blood urine nitrogen (BUN), Creatinine, uric acid, Na, K, complete blood count (CBC), and Reticulocyte count checked for patients.</offsets></p><p><offsets xml_i="10220" xml_f="10333" txt_i="4944" txt_f="5057">Patients re-evaluated at days 14 and 28 and NIHSS was assessed by another neurologist blinded to patient's group.</offsets></p><p><offsets xml_i="10340" xml_f="10405" txt_i="5058" txt_f="5123">Finally, NIHSS changes of both groups analyzed by SPSS software [</offsets><xref ref-type="table" rid="T1"><offsets xml_i="10437" xml_f="10444" txt_i="5123" txt_f="5130">Table 1</offsets></xref><offsets xml_i="10451" xml_f="10453" txt_i="5130" txt_f="5132">].</offsets></p><table-wrap id="T1" position="float"><label><offsets xml_i="10501" xml_f="10508" txt_i="5133" txt_f="5140">Table 1</offsets></label><caption><p><offsets xml_i="10528" xml_f="10579" txt_i="5140" txt_f="5191">Patients distribution based on EPO in men and women</offsets></p></caption><graphic xlink:href="IJPVM-4-306-g001"></graphic></table-wrap></sec><sec sec-type="results" id="sec1-3"><title><offsets xml_i="10704" xml_f="10711" txt_i="5193" txt_f="5200">RESULTS</offsets></title><p><offsets xml_i="10722" xml_f="11137" txt_i="5201" txt_f="5616">This study was carried out between April 2009 and June 2010 in three university hospitals in Tehran and Isfahan, Iran. On a total of 67 patients treated with erythropoietin but 30 of them were excluded. The most common cause was deterioration of patient's general condition due to systemic infections particularly pneumonia, bedsore, and second stroke, which significantly damaged patient's condition and responses.</offsets></p><p><offsets xml_i="11144" xml_f="11304" txt_i="5617" txt_f="5777">Thirty seven patients of erythropoietin group and 43 of control group completed study. Mean of age was 64.19 and 67.56 in case and control groups respectively [</offsets><xref ref-type="table" rid="T2"><offsets xml_i="11336" xml_f="11343" txt_i="5777" txt_f="5784">Table 2</offsets></xref><offsets xml_i="11350" xml_f="11352" txt_i="5784" txt_f="5786">].</offsets></p><table-wrap id="T2" position="float"><label><offsets xml_i="11400" xml_f="11407" txt_i="5787" txt_f="5794">Table 2</offsets></label><caption><p><offsets xml_i="11427" xml_f="11501" txt_i="5794" txt_f="5868">Mean and standard deviation of age and scores of NIHSS of the participants</offsets></p></caption><graphic xlink:href="IJPVM-4-306-g002"></graphic></table-wrap><p><offsets xml_i="11580" xml_f="11734" txt_i="5869" txt_f="6023">Initial total score of NIHSS was 9.03 ± 4.83 in erythropoietin group and 9.70 ± 5.82 in control group, which had not statistically significant difference.</offsets></p><p><offsets xml_i="11741" xml_f="11877" txt_i="6024" txt_f="6160">After 2 weeks, total NIHSS decreased to 3.35 ± 2.17 in case group and 7.95 ± 5.65 in control group, which were significantly different (</offsets><italic><offsets xml_i="11885" xml_f="11886" txt_i="6160" txt_f="6161">P</offsets></italic><offsets xml_i="11895" xml_f="11906" txt_i="6161" txt_f="6172"> = 0.0001).</offsets></p><p><offsets xml_i="11913" xml_f="12046" txt_i="6173" txt_f="6306">After 4 weeks, total NIHSS reached to 2.11 ± 1.61 in case group and 6.05 ± 4.87 in control group, which are significantly different (</offsets><italic><offsets xml_i="12054" xml_f="12055" txt_i="6306" txt_f="6307">P</offsets></italic><offsets xml_i="12064" xml_f="12076" txt_i="6307" txt_f="6319"> = 0.0001) [</offsets><xref ref-type="table" rid="T3"><offsets xml_i="12108" xml_f="12115" txt_i="6319" txt_f="6326">Table 3</offsets></xref><offsets xml_i="12122" xml_f="12124" txt_i="6326" txt_f="6328">].</offsets></p><table-wrap id="T3" position="float"><label><offsets xml_i="12172" xml_f="12179" txt_i="6329" txt_f="6336">Table 3</offsets></label><caption><p><offsets xml_i="12199" xml_f="12264" txt_i="6336" txt_f="6401">Mean difference and standard error difference of the NIHSS scores</offsets></p></caption><graphic xlink:href="IJPVM-4-306-g003"></graphic></table-wrap><p><offsets xml_i="12343" xml_f="12558" txt_i="6402" txt_f="6617">Level of consciousness (LOC) commands score was 0.35 ± 0.716 in erythropoietin and 0.51 ± 0.827 in control group as the first assessment. After 2 weeks, they decreased to 0.03 ± 0.164 and 0.33 ± 0.680 respectively (</offsets><italic><offsets xml_i="12566" xml_f="12567" txt_i="6617" txt_f="6618">P</offsets></italic><offsets xml_i="12576" xml_f="12719" txt_i="6618" txt_f="6761"> = 0.008). After 4 weeks, they reached to 0.00 ± 0.000 in erythropoietin and 0.12 ± 0.324 in control groups, which had significant difference (</offsets><italic><offsets xml_i="12727" xml_f="12728" txt_i="6761" txt_f="6762">P</offsets></italic><offsets xml_i="12737" xml_f="12747" txt_i="6762" txt_f="6772"> = 0.024).</offsets></p><p><offsets xml_i="12754" xml_f="12953" txt_i="6773" txt_f="6972">Initially, facial palsy score in erythropoietin group was 1.16 ± 0.958 and in control group was 1.16 ± 0.814.After 2 week, they decreased to 0.59 ± 0.599 and 1.09 ± 0.781 in two groups respectively (</offsets><italic><offsets xml_i="12961" xml_f="12962" txt_i="6972" txt_f="6973">P</offsets></italic><offsets xml_i="12971" xml_f="13110" txt_i="6973" txt_f="7112"> = 0.002). After 4 weeks, it was 0.38 ± 0.492 in erythropoietin group and 0.84 ± 0.814 in control group, which had significant difference (</offsets><italic><offsets xml_i="13118" xml_f="13119" txt_i="7112" txt_f="7113">P</offsets></italic><offsets xml_i="13128" xml_f="13138" txt_i="7113" txt_f="7123"> = 0.003).</offsets></p><p><offsets xml_i="13145" xml_f="13343" txt_i="7124" txt_f="7322">Upper limbs movement score was 2.43 ± 1.144 in erythropoietin and 2.44 ± 1.053 in control group as the first assessment. After 2 weeks, they decreased to 1.03 ± 0.763 and 2.23 ± 1.109 respectively (</offsets><italic><offsets xml_i="13351" xml_f="13352" txt_i="7322" txt_f="7323">P</offsets></italic><offsets xml_i="13361" xml_f="13505" txt_i="7323" txt_f="7467"> = 0.0001). After 4 weeks, they reached to 0.57 ± 0.502 in erythropoietin and 1.88 ± 1.219 in control groups, which had significant difference (</offsets><italic><offsets xml_i="13513" xml_f="13514" txt_i="7467" txt_f="7468">P</offsets></italic><offsets xml_i="13523" xml_f="13534" txt_i="7468" txt_f="7479"> = 0.0001).</offsets></p><p><offsets xml_i="13541" xml_f="13739" txt_i="7480" txt_f="7678">Lower limbs movement score was 2.32 ± 1.292 in erythropoietin and 2.16 ± 1.233 in control group as the first assessment. After 2 weeks, they decreased to 1.00 ± 0.782 and 2.05 ± 1.194 respectively (</offsets><italic><offsets xml_i="13747" xml_f="13748" txt_i="7678" txt_f="7679">P</offsets></italic><offsets xml_i="13757" xml_f="13901" txt_i="7679" txt_f="7823"> = 0.0001). After 4 weeks, they reached to 0.65 ± 0.588 in erythropoietin and 1.74 ± 1.236 in control groups, which had significant difference (</offsets><italic><offsets xml_i="13909" xml_f="13910" txt_i="7823" txt_f="7824">P</offsets></italic><offsets xml_i="13919" xml_f="13930" txt_i="7824" txt_f="7835"> = 0.0001).</offsets></p><p><offsets xml_i="13937" xml_f="14132" txt_i="7836" txt_f="8031">Initially, sensory score in erythropoietin group was 0.24 ± 0.435 and in control group was 0.37 ± 0.757. After 2 week, they decreased to 0.00 ± 0.000 and 0.33 ± 0.747 in two groups respectively (</offsets><italic><offsets xml_i="14140" xml_f="14141" txt_i="8031" txt_f="8032">P</offsets></italic><offsets xml_i="14150" xml_f="14289" txt_i="8032" txt_f="8171"> = 0.007). After 4 weeks, it was 0.00 ± 0.000 in erythropoietin group and 0.28 ± 0.666 in control group, which had significant difference (</offsets><italic><offsets xml_i="14297" xml_f="14298" txt_i="8171" txt_f="8172">P</offsets></italic><offsets xml_i="14307" xml_f="14317" txt_i="8172" txt_f="8182"> = 0.009).</offsets></p><p><offsets xml_i="14324" xml_f="14528" txt_i="8183" txt_f="8387">And finally, best language score was 0.70 ± 0.968 in erythropoietin and 0.63 ± 1.024 in control group as the first assessment. After 2 weeks, they decreased to 0.19 ± 0.397 and 0.53 ± 1.032 respectively (</offsets><italic><offsets xml_i="14536" xml_f="14537" txt_i="8387" txt_f="8388">P</offsets></italic><offsets xml_i="14546" xml_f="14689" txt_i="8388" txt_f="8531"> = 0.047). After 4 weeks, they reached to 0.08 ± 0.277 in erythropoietin and 0.37 ± 0.757 in control groups, which had significant difference (</offsets><italic><offsets xml_i="14697" xml_f="14698" txt_i="8531" txt_f="8532">P</offsets></italic><offsets xml_i="14707" xml_f="14718" txt_i="8532" txt_f="8543"> = 0.023) [</offsets><xref ref-type="table" rid="T4"><offsets xml_i="14750" xml_f="14757" txt_i="8543" txt_f="8550">Table 4</offsets></xref><offsets xml_i="14764" xml_f="14766" txt_i="8550" txt_f="8552">].</offsets></p><table-wrap id="T4" position="float"><label><offsets xml_i="14814" xml_f="14821" txt_i="8553" txt_f="8560">Table 4</offsets></label><caption><p><offsets xml_i="14841" xml_f="14914" txt_i="8560" txt_f="8633">Mean and standard deviation of outcome variables in EPO and no EPO groups</offsets></p></caption><graphic xlink:href="IJPVM-4-306-g004"></graphic></table-wrap><p><offsets xml_i="14993" xml_f="15111" txt_i="8634" txt_f="8752">Other parts of NIHSS showed no significant difference between two groups after 4 weeks. Results are shown in appendix.</offsets></p></sec><sec sec-type="conclusions" id="sec1-4"><title><offsets xml_i="15168" xml_f="15179" txt_i="8754" txt_f="8765">CONCLUSIONS</offsets></title><p><offsets xml_i="15190" xml_f="16015" txt_i="8766" txt_f="9591">As noted stroke is the third leading cause of death and stroke prevention by modifying related risk-factors, such as alcohol consumption, smoking, oral contraceptives, hypertension, and hyperlipidemia is very important. However, an important question is what can we do in acute phase of stroke? Nearly two-third of strokes is ischemic and various treatments are introduced for acute ischemic strokes, which are diagnosed by prompt neuroimaging. Antiplatelet drugs such as aspirin and anticoagulants including, heparin and warfarin are the most current treatments. Some other treatments such as vitamin E, vitamin C, Citicoline, minocycline, and folic acid are suggested with lesser importance. Some controlled clinical data but not all of them are in favor of recombinant tissue plasminogen activator (rt-PA). Treatment with </offsets><italic><offsets xml_i="16023" xml_f="16024" txt_i="9591" txt_f="9592">t</offsets></italic><offsets xml_i="16033" xml_f="16138" txt_i="9592" txt_f="9697">-PA within 3 h after onset of symptoms lowers mortality and morbidity. The most important side-effect of </offsets><italic><offsets xml_i="16146" xml_f="16147" txt_i="9697" txt_f="9698">t</offsets></italic><offsets xml_i="16156" xml_f="16234" txt_i="9698" txt_f="9776">-PA is intracranial hemorrhage therefore, some limitations are defined to use </offsets><italic><offsets xml_i="16242" xml_f="16243" txt_i="9776" txt_f="9777">t</offsets></italic><offsets xml_i="16252" xml_f="16273" txt_i="9777" txt_f="9798">-PA in acute stroke.[</offsets><xref ref-type="bibr" rid="ref17"><offsets xml_i="16307" xml_f="16309" txt_i="9798" txt_f="9800">17</offsets></xref><offsets xml_i="16316" xml_f="16317" txt_i="9800" txt_f="9801">–</offsets><xref ref-type="bibr" rid="ref20"><offsets xml_i="16351" xml_f="16353" txt_i="9801" txt_f="9803">20</offsets></xref><offsets xml_i="16360" xml_f="16361" txt_i="9803" txt_f="9804">]</offsets></p><p><offsets xml_i="16368" xml_f="16862" txt_i="9805" txt_f="10299">Treatments to increase brain cell tolerance to ischemic and hypoxic insults can improve survival and rehabilitation course. New studies show some receptors for erythropoietin are detectable not only in brain but also in peripheral nervous system, cerebrospinal fluid and retina. Erythropoietin seems to be a cytokine with neuroprotective and neurotrophic effects on central and peripheral nervous systems. Some studies show effectiveness of erythropoietin in regeneration of peripheral nerves.[</offsets><xref ref-type="bibr" rid="ref21"><offsets xml_i="16896" xml_f="16898" txt_i="10299" txt_f="10301">21</offsets></xref><offsets xml_i="16905" xml_f="16906" txt_i="10301" txt_f="10302">–</offsets><xref ref-type="bibr" rid="ref29"><offsets xml_i="16940" xml_f="16942" txt_i="10302" txt_f="10304">29</offsets></xref><offsets xml_i="16949" xml_f="16950" txt_i="10304" txt_f="10305">]</offsets></p><p><offsets xml_i="16957" xml_f="17024" txt_i="10306" txt_f="10373">New studies show simultaneous administration of erythropoietin and </offsets><italic><offsets xml_i="17032" xml_f="17033" txt_i="10373" txt_f="10374">t</offsets></italic><offsets xml_i="17042" xml_f="17099" txt_i="10374" txt_f="10431">-PA is harmful and leads to increase mortality. Zecharia </offsets><italic><offsets xml_i="17107" xml_f="17112" txt_i="10431" txt_f="10436">et al</offsets></italic><offsets xml_i="17121" xml_f="17179" txt_i="10436" txt_f="10494">. reported cellular DNA fracture in-patients who received </offsets><italic><offsets xml_i="17187" xml_f="17188" txt_i="10494" txt_f="10495">t</offsets></italic><offsets xml_i="17197" xml_f="17255" txt_i="10495" txt_f="10553">-PA after treatment by erythropoietin in an animal model.[</offsets><xref ref-type="bibr" rid="ref30"><offsets xml_i="17289" xml_f="17291" txt_i="10553" txt_f="10555">30</offsets></xref><offsets xml_i="17298" xml_f="17324" txt_i="10555" txt_f="10581">] In addition, Ehrenreich </offsets><italic><offsets xml_i="17332" xml_f="17337" txt_i="10581" txt_f="10586">et al</offsets></italic><offsets xml_i="17346" xml_f="17416" txt_i="10586" txt_f="10656">. reported uselessness of concomitant treatment of erythropoietin and </offsets><italic><offsets xml_i="17424" xml_f="17425" txt_i="10656" txt_f="10657">t</offsets></italic><offsets xml_i="17434" xml_f="17438" txt_i="10657" txt_f="10661">-PA[</offsets><xref ref-type="bibr" rid="ref31"><offsets xml_i="17472" xml_f="17474" txt_i="10661" txt_f="10663">31</offsets></xref><offsets xml_i="17481" xml_f="17582" txt_i="10663" txt_f="10764">] although, his study in 2002 showed high-dose erythropoietin in acute stroke is safe and effective.[</offsets><xref ref-type="bibr" rid="ref32"><offsets xml_i="17616" xml_f="17618" txt_i="10764" txt_f="10766">32</offsets></xref><offsets xml_i="17625" xml_f="17626" txt_i="10766" txt_f="10767">]</offsets></p><p><offsets xml_i="17633" xml_f="17822" txt_i="10768" txt_f="10957">In this study, erythropoietin group had better outcome in comparison to control group. Total NIHSS was significantly lower in erythropoietin group. This effectwas of value in LOC Commands (</offsets><italic><offsets xml_i="17830" xml_f="17831" txt_i="10957" txt_f="10958">P</offsets></italic><offsets xml_i="17840" xml_f="17864" txt_i="10958" txt_f="10982">= 0.024), facial palsy (</offsets><italic><offsets xml_i="17872" xml_f="17873" txt_i="10982" txt_f="10983">P</offsets></italic><offsets xml_i="17882" xml_f="17903" txt_i="10983" txt_f="11004">= 0.003), motor arm (</offsets><italic><offsets xml_i="17911" xml_f="17912" txt_i="11004" txt_f="11005">P</offsets></italic><offsets xml_i="17921" xml_f="17943" txt_i="11005" txt_f="11027">= 0.0001), motor leg (</offsets><italic><offsets xml_i="17951" xml_f="17952" txt_i="11027" txt_f="11028">P</offsets></italic><offsets xml_i="17961" xml_f="17981" txt_i="11028" txt_f="11048">= 0.0001), sensory (</offsets><italic><offsets xml_i="17989" xml_f="17990" txt_i="11048" txt_f="11049">P</offsets></italic><offsets xml_i="17999" xml_f="18028" txt_i="11049" txt_f="11078">= 0.009), and best language (</offsets><italic><offsets xml_i="18036" xml_f="18037" txt_i="11078" txt_f="11079">P</offsets></italic><offsets xml_i="18046" xml_f="18055" txt_i="11079" txt_f="11088">= 0.023).</offsets></p><p><offsets xml_i="18062" xml_f="18484" txt_i="11089" txt_f="11511">A major limitation in this study was high number of patients, which excluded even after complete administration of erythropoietin because some unwanted conditions such as infections. In addition, patients with high NIHSS rate had poorer condition and more risk for infection and bedsore andhence these patients were more prone to be excluded. Therefore, majority of our cases were gathered in patients with low NIHSS rate.</offsets></p><p><offsets xml_i="18491" xml_f="18846" txt_i="11512" txt_f="11867">In Iran, we frequently encountered patients with acute ischemic stroke, which arrive in emergency room after 3 h. So erythropoietin could be helpful to treat patients with acute ischemic stroke in this condition. We believe complementary studies are needed to establish the best dose and the most effective interval between stroke and drug administration.</offsets></p></sec></body><back><fn-group><fn fn-type="supported-by"><p><bold>Source of Support:</bold> Nil</p></fn><fn fn-type="conflict"><p><bold>Conflict of Interest:</bold> None declared.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baldwin</surname><given-names>K</given-names></name><name><surname>Orr</surname><given-names>S</given-names></name><name><surname>Briand</surname><given-names>M</given-names></name><name><surname>Piazza</surname><given-names>C</given-names></name><name><surname>Veydt</surname><given-names>A</given-names></name><name><surname>McCoy</surname><given-names>S</given-names></name></person-group><article-title>Acute ischemic stroke update</article-title><source>Pharmacotherapy</source><year>2010</year><volume>30</volume><fpage>493</fpage><lpage>514</lpage><pub-id pub-id-type="pmid">20412000</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>JK</given-names></name><name><surname>Portbury</surname><given-names>S</given-names></name><name><surname>Thomas</surname><given-names>MB</given-names></name><name><surname>Barney</surname><given-names>S</given-names></name><name><surname>Ricca</surname><given-names>DJ</given-names></name><name><surname>Morris</surname><given-names>DL</given-names></name><etal></etal></person-group><article-title>Cardiac glycosides provide neuroprotection against ischemic stroke: Discovery by a brain slice-based compound screening platform</article-title><source>Proc Natl Acad Sci USA</source><year>2006</year><volume>103</volume><fpage>10461</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">16793926</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sallar</surname><given-names>AM</given-names></name><name><surname>Williams</surname><given-names>PB</given-names></name><name><surname>Omishakin</surname><given-names>AM</given-names></name><name><surname>Lloyd</surname><given-names>DP</given-names></name></person-group><article-title>Stroke prevention: Awareness of risk factors for stroke among African American residents in the Mississippi delta region</article-title><source>J Natl Med Assoc</source><year>2010</year><volume>102</volume><fpage>84</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">20191920</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyers</surname><given-names>PM</given-names></name><name><surname>Schumacher</surname><given-names>HC</given-names></name><etal></etal></person-group><collab>Writing Group for the American Academy of Neurology, AANS/CNS Cerebrovascular Section, Society of NeuroInterventional Surgery, Society of Vascular and Interventional Neurology</collab><article-title>Performance and training standards for endovascular ischemic stroke treatment</article-title><source>AJNR Am J Neuroradiol</source><year>2010</year><volume>31</volume><fpage>E8</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">20075105</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyers</surname><given-names>PM</given-names></name><name><surname>Schumacher</surname><given-names>HC</given-names></name><name><surname>Alexander</surname><given-names>MJ</given-names></name><name><surname>Derdeyn</surname><given-names>CP</given-names></name><name><surname>Furlan</surname><given-names>AJ</given-names></name><name><surname>Higashida</surname><given-names>RT</given-names></name><etal></etal></person-group><article-title>Performance and training standards for endovascular ischemic stroke treatment</article-title><source>J Neurosurg</source><year>2010</year><volume>113</volume><fpage>149</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">20035576</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flemming</surname><given-names>KD</given-names></name><name><surname>Brown</surname><given-names>RD</given-names><suffix>Jr</suffix></name></person-group><article-title>Secondary prevention strategies in ischemic stroke: Identification and optimal management of modifiable risk factors</article-title><source>Mayo Clin Proc</source><year>2004</year><volume>79</volume><fpage>1330</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">15473419</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albers</surname><given-names>GW</given-names></name><name><surname>Caplan</surname><given-names>LR</given-names></name><name><surname>Easton</surname><given-names>JD</given-names></name><name><surname>Fayad</surname><given-names>PB</given-names></name><name><surname>Mohr</surname><given-names>JP</given-names></name><name><surname>Saver</surname><given-names>JL</given-names></name><etal></etal></person-group><article-title>Transient ischemic attack– Proposal for a new definition</article-title><source>N Engl J Med</source><year>2002</year><volume>347</volume><fpage>1713</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">12444191</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caplan</surname><given-names>LR</given-names></name></person-group><article-title>Transient ischemic attack: Definition and natural history</article-title><source>Curr Atheroscler Rep</source><year>2006</year><volume>8</volume><fpage>276</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">16822392</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landau</surname><given-names>WM</given-names></name></person-group><article-title>Causes of stroke</article-title><source>Ann Neurol</source><year>1992</year><volume>32</volume><fpage>596</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">1456750</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>SH</given-names></name><name><surname>Jung</surname><given-names>JM</given-names></name></person-group><article-title>Risk factors for acute cardioembolic brain stroke in acute myocardial infarction</article-title><source>Korean Circ J</source><year>2005</year><volume>35</volume><fpage>353</fpage><lpage>6</lpage></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohira</surname><given-names>T</given-names></name><name><surname>Shahar</surname><given-names>E</given-names></name><name><surname>Chambless</surname><given-names>LE</given-names></name><name><surname>Rosamond</surname><given-names>WD</given-names></name><name><surname>Mosley</surname><given-names>TH</given-names><suffix>Jr</suffix></name><name><surname>Folsom</surname><given-names>AR</given-names></name></person-group><article-title>Risk factors for ischemic stroke subtypes: The atherosclerosis risk in communities study</article-title><source>Stroke</source><year>2006</year><volume>37</volume><fpage>2493</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">16931783</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ong</surname><given-names>TZ</given-names></name><name><surname>Raymond</surname><given-names>AA</given-names></name></person-group><article-title>Risk factors for stroke and predictors of one-month mortality</article-title><source>Singapore Med J</source><year>2002</year><volume>43</volume><fpage>517</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">12587706</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marwat</surname><given-names>MA</given-names></name><name><surname>Usman</surname><given-names>M</given-names></name><name><surname>Hussain</surname><given-names>M</given-names></name></person-group><article-title>Stroke and its relationship between to risk factors</article-title><source>Gomal J Med Sci</source><year>2009</year><volume>7</volume><fpage>17</fpage><lpage>20</lpage></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bilić</surname><given-names>I</given-names></name><name><surname>Dzamonja</surname><given-names>G</given-names></name><name><surname>Lusić</surname><given-names>I</given-names></name><name><surname>Matijaca</surname><given-names>M</given-names></name><name><surname>Caljkusić</surname><given-names>K</given-names></name></person-group><article-title>Risk factors and outcome differences between ischemic and hemorrhagic stroke</article-title><source>Acta Clin Croat</source><year>2009</year><volume>48</volume><fpage>399</fpage><lpage>403</lpage><pub-id pub-id-type="pmid">20405634</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Aminoff</surname><given-names>MJ</given-names></name><name><surname>Greenberg</surname><given-names>DA</given-names></name><name><surname>Simon</surname><given-names>RP</given-names></name></person-group><source>Clinical Neurology</source><year>2005</year><edition>6th ed</edition><publisher-loc>New York</publisher-loc><publisher-name>Mc Graw Hill</publisher-name><fpage>285</fpage></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Chopp</surname><given-names>M</given-names></name></person-group><article-title>Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats</article-title><source>Stroke</source><year>2004</year><volume>35</volume><fpage>1732</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">15178821</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name><surname>Lewartowski</surname><given-names>BL</given-names></name></person-group><article-title>Erythropoietin in treatment of heart failure and ischemia. FAC. Federacion Argentina de Cardiologia</article-title><source>5<sup>th</sup> Virtual Congress of Cardiology–QVCC. Department of Clinical Physiology, Medical Center of Postgraduate Education, Warsaw, Poland</source><date-in-citation>Last Cited 2013 Jan 20</date-in-citation><comment>Available from:
<uri xlink:type="simple" xlink:href="http://www.fac.org.ar/qcvc/llave/c126i/lewartowski.php">http://www.fac.org.ar/qcvc/llave/c126i/lewartowski.php</uri></comment></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brott</surname><given-names>T</given-names></name><name><surname>Bogousslavsky</surname><given-names>J</given-names></name></person-group><article-title>Treatment of acute ischemic stroke</article-title><source>N Engl J Med</source><year>2000</year><volume>343</volume><fpage>710</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">10974136</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>DZ</given-names></name><name><surname>Rose</surname><given-names>JA</given-names></name><name><surname>Honings</surname><given-names>DS</given-names></name><name><surname>Garwacki</surname><given-names>DJ</given-names></name><name><surname>Milbrandt</surname><given-names>JC</given-names></name></person-group><article-title>Treating acute stroke patients with intravenous tPA. The OSF stroke network experience</article-title><source>Stroke</source><year>2000</year><volume>31</volume><fpage>77</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">10625719</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Wolf-Dieter</surname><given-names>H</given-names></name></person-group><article-title>Systemic rtPA in Patients with Acute Ischemic Stroke. Max-Planck-Institut für neurologische Forschung, Köln, Germany</article-title><source>Emergency treatment for a stroke</source><year>2009</year><publisher-name>BMJ Publishing Group Limited</publisher-name></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>XB</given-names></name><name><surname>Wang</surname><given-names>JA</given-names></name><name><surname>Yu</surname><given-names>SP</given-names></name><name><surname>Keogh</surname><given-names>CL</given-names></name><name><surname>Wei</surname><given-names>L</given-names></name></person-group><article-title>Therapeutic strategy of erythropoietin in neurological disorders</article-title><source>CNS Neurol Disord Drug Targets</source><year>2008</year><volume>7</volume><fpage>227</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">18673207</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>PT</given-names></name><name><surname>Ohab</surname><given-names>JJ</given-names></name><name><surname>Kertesz</surname><given-names>N</given-names></name><name><surname>Groszer</surname><given-names>M</given-names></name><name><surname>Matter</surname><given-names>C</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>A critical role of erythropoietin receptor in neurogenesis and post-stroke recovery</article-title><source>J Neurosci</source><year>2006</year><volume>26</volume><fpage>1269</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">16436614</pub-id></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ntaios</surname><given-names>G</given-names></name><name><surname>Savopoulos</surname><given-names>C</given-names></name><name><surname>Chatzinikolaou</surname><given-names>A</given-names></name><name><surname>Hatzitolios</surname><given-names>AI</given-names></name></person-group><article-title>The neuroprotective role of erythropoietin in the management of acute ischaemic stroke: From bench to bedside</article-title><source>Acta Neurol Scand</source><year>2008</year><volume>118</volume><fpage>362</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">18513348</pub-id></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Kooij</surname><given-names>MA</given-names></name><name><surname>Groenendaal</surname><given-names>F</given-names></name><name><surname>Kavelaars</surname><given-names>A</given-names></name><name><surname>Heijnen</surname><given-names>CJ</given-names></name><name><surname>van Bel</surname><given-names>F</given-names></name></person-group><article-title>Neuroprotective properties and mechanisms of erythropoietin in <italic>in vitro</italic> and <italic>in vivo</italic> experimental models for hypoxia/ischemia</article-title><source>Brain Res Rev</source><year>2008</year><volume>59</volume><fpage>22</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">18514916</pub-id></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwai</surname><given-names>M</given-names></name><name><surname>Cao</surname><given-names>G</given-names></name><name><surname>Yin</surname><given-names>W</given-names></name><name><surname>Stetler</surname><given-names>RA</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name></person-group><article-title>Erythropoietin promotes neuronal replacement through revascularization and neurogenesis after neonatal hypoxia/ischemia in rats</article-title><source>Stroke</source><year>2007</year><volume>38</volume><fpage>2795</fpage><lpage>803</lpage><pub-id pub-id-type="pmid">17702962</pub-id></element-citation></ref><ref id="ref26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lapchak</surname><given-names>PA</given-names></name><name><surname>Kirkeby</surname><given-names>A</given-names></name><name><surname>Zivin</surname><given-names>JA</given-names></name><name><surname>Sager</surname><given-names>TN</given-names></name></person-group><article-title>Therapeutic window for nonerythropoietic carbamylated-erythropoietin to improve motor function following multiple infarct ischemic strokes in New Zealand white rabbits</article-title><source>Brain Res</source><year>2008</year><volume>1238</volume><fpage>208</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">18761001</pub-id></element-citation></ref><ref id="ref27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Sun</surname><given-names>B</given-names></name><name><surname>Yu</surname><given-names>Z</given-names></name><name><surname>An</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Ren</surname><given-names>T</given-names></name></person-group><article-title>High dose erythropoietin promotes functional recovery of rats following facial nerve crush</article-title><source>J Clin Neurosci</source><year>2009</year><volume>16</volume><fpage>554</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">19231194</pub-id></element-citation></ref><ref id="ref28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lykissas</surname><given-names>MG</given-names></name><name><surname>Sakellariou</surname><given-names>E</given-names></name><name><surname>Vekris</surname><given-names>MD</given-names></name><name><surname>Kontogeorgakos</surname><given-names>VA</given-names></name><name><surname>Batistatou</surname><given-names>AK</given-names></name><name><surname>Mitsionis</surname><given-names>GI</given-names></name><etal></etal></person-group><article-title>Axonal regeneration stimulated by erythropoietin: An experimental study in rats</article-title><source>J Neurosci Methods</source><year>2007</year><volume>164</volume><fpage>107</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">17532473</pub-id></element-citation></ref><ref id="ref29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalialis</surname><given-names>LV</given-names></name><name><surname>Olsen</surname><given-names>NV</given-names></name></person-group><article-title>Erythropoietin– A new therapy in cerebral ischemia?</article-title><source>Ugeskr Laeger</source><year>2003</year><volume>165</volume><fpage>2477</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">12872467</pub-id></element-citation></ref><ref id="ref30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zechariah</surname><given-names>A</given-names></name><name><surname>ElAli</surname><given-names>A</given-names></name><name><surname>Hermann</surname><given-names>DM</given-names></name></person-group><article-title>Combination of tissue-plasminogen activator with erythropoietin induces blood-brain barrier permeability, extracellular matrix disaggregation, and DNA fragmentation after focal cerebral ischemia in mice</article-title><source>Stroke</source><year>2010</year><volume>41</volume><fpage>1008</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">20360548</pub-id></element-citation></ref><ref id="ref31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ehrenreich</surname><given-names>H</given-names></name><name><surname>Weissenborn</surname><given-names>K</given-names></name><name><surname>Prange</surname><given-names>H</given-names></name><name><surname>Schneider</surname><given-names>D</given-names></name><name><surname>Weimar</surname><given-names>C</given-names></name><name><surname>Wartenberg</surname><given-names>K</given-names></name><etal></etal></person-group><article-title>Recombinant human erythropoietin in the treatment of acute ischemic stroke</article-title><source>Stroke</source><year>2009</year><volume>40</volume><fpage>647</fpage><lpage>56</lpage></element-citation></ref><ref id="ref32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ehrenreich</surname><given-names>H</given-names></name><name><surname>Hasselblatt</surname><given-names>M</given-names></name><name><surname>Dembowski</surname><given-names>C</given-names></name><name><surname>Cepek</surname><given-names>L</given-names></name><name><surname>Lewczuk</surname><given-names>P</given-names></name><name><surname>Stiefel</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Erythropoietin therapy for acute stroke is both safe and beneficial</article-title><source>Mol Med</source><year>2002</year><volume>8</volume><fpage>495</fpage><lpage>505</lpage><pub-id pub-id-type="pmid">12435860</pub-id></element-citation></ref></ref-list></back></article>